Jan 122019

NEQUIMED/IQSC/USP, in partnership with groups specialized in parasitology of Trypanosoma cruzi, the agent that causes Chagas disease, identifies new drug candidates for the treatment of this disease. One of the key steps in the drug pipeline at this stage of the process is the scaling-up of the synthesis for the production of the desired grams-scale products. In vivo assays are now essential for the evaluation of potency and early toxicity, with consequent determination of dosage. Synthetic chemists eager to contribute to synthetic medical chemistry with scaled-up and improved reaction yields are welcome to join our group. Interested parties should send a message through our contacts.